JPH07304686A - Melanin synthesis-inhibiting agent - Google Patents
Melanin synthesis-inhibiting agentInfo
- Publication number
- JPH07304686A JPH07304686A JP6119534A JP11953494A JPH07304686A JP H07304686 A JPH07304686 A JP H07304686A JP 6119534 A JP6119534 A JP 6119534A JP 11953494 A JP11953494 A JP 11953494A JP H07304686 A JPH07304686 A JP H07304686A
- Authority
- JP
- Japan
- Prior art keywords
- growth factor
- fibroblast growth
- melanin synthesis
- inhibiting agent
- melanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、シミ、ソバカス、日焼
け等色素沈着の原因となるメラニン合成を抑えるため
の、線維芽細胞成長因子を用いたメラニン合成抑制剤に
関するものである。TECHNICAL FIELD The present invention relates to a melanin synthesis inhibitor using fibroblast growth factor for suppressing melanin synthesis which causes pigmentation such as spots, freckles and sunburn.
【０００２】[0002]
【従来の技術】シミ、ソバカス等色素沈着を抑えること
は美顔術の重要な要素であり、更に日焼けの予防、回復
に対する関心も高い。現在、色素沈着を抑えるメラニン
合成抑制物質として、ｐ−ヒドロキシシンナムアミド誘
導体（特願昭６１−１８３０６８）、Ｎ，Ｎ−ジアルキ
ル−ｐ−ヒドロキシシンナムアミド、Ｎ−（ｐ−ヒドロ
キシシンナモイル）グリシン、２−アミノエタンスルホ
ン酸（特願平２−１６０３７３）、ベンジルフェニルケ
トン誘導体、ストレプトコッカス属またはラクトコッカ
ス属の菌体抽出物、ビスアリールスルフィド誘導体、ア
リールスルフィド誘導体等が用いられているが、化学物
質であるため肌あれ等の可能性がある。そこで色素沈着
を抑え、肌に優しい生体由来のメラニン合成抑制物質の
開発が求められていた。2. Description of the Related Art Suppression of pigmentation such as spots and freckles is an important factor in facial surgery, and there is a great interest in the prevention and recovery of sunburn. Currently, p-hydroxycinnamamide derivatives (Japanese Patent Application No. 61-183068), N, N-dialkyl-p-hydroxycinnamamides, and N- (p-hydroxycinnamoyl) are used as melanin synthesis inhibitors that suppress pigmentation. Glycine, 2-aminoethanesulfonic acid (Japanese Patent Application No. 2-160373), benzyl phenyl ketone derivative, Streptococcus genus or Lactococcus genus cell extract, bisaryl sulfide derivative, aryl sulfide derivative, etc. are used. Since it is a chemical substance, it may cause skin irritation. Therefore, there has been a demand for the development of a biologically-derived melanin synthesis inhibitor that suppresses pigmentation and is gentle on the skin.
【０００３】[0003]
【発明が解決しようとする課題】本発明は上記のような
色素沈着抑制物質に関する問題点を解決し、肌に優しい
生体成分からなるメラニン合成抑制剤を提供することを
目的とした。SUMMARY OF THE INVENTION It is an object of the present invention to solve the above-mentioned problems associated with pigmentation-inhibiting substances and to provide a melanin synthesis inhibitor comprising a biological component that is gentle to the skin.
【０００４】[0004]
【課題を解決するための手段】本発明者らは、上記目的
を達成するために鋭意研究を重ねた結果、生体由来物質
である線維芽細胞成長因子が強いメラニン合成抑制作用
を有していることを明らかにすることに成功し、本発明
を完成するに至った。Means for Solving the Problems As a result of intensive studies for achieving the above-mentioned object, the present inventors have found that fibroblast growth factor, which is a biological substance, has a strong inhibitory effect on melanin synthesis. We succeeded in clarifying this and completed the present invention.
【０００５】線維芽細胞成長因子は１９７４年にＤ．Ｇ
ｏｓｐｏｄａｒｏｗｉｃｚによって、脳下垂体より発見
されたペプチド性細胞成長因子であり、宝酒造株式会社
などから発売されているので、そこから入手することが
可能である。本因子は血管内皮細胞、線維芽細胞を含む
ほとんどすべての中胚葉由来細胞に対して細胞増殖刺激
活性を有することが明らかとなっている。主な線維芽細
胞成長因子には等電点が塩基性（ｐＩ ９．６）の塩基
性線維芽細胞成長因子（ｂＦＧＦ）と、酸性（ｐＩ ５
−７）の酸性線維芽細胞成長因子（ａＦＧＦ）があり、
分子量は共に１６ｋＤの糖を含まない単鎖ポリペプチド
である。細胞増殖刺激活性は塩基性線維芽細胞成長因子
の方が酸性線維芽細胞成長因子よりも３０−１００倍高
いと言われている。Fibroblast growth factor was first described in 1974 by D. G
It is a peptide-based cell growth factor discovered by ospodarowicz from the pituitary gland, and it is available from Takara Shuzo Co., Ltd. and the like, and can be obtained from there. It has been revealed that this factor has a cell growth-stimulating activity on almost all mesodermal-derived cells including vascular endothelial cells and fibroblasts. Major fibroblast growth factors include basic fibroblast growth factor (bFGF) having a basic isoelectric point (pI 9.6) and acidic (pI 5).
-7) acidic fibroblast growth factor (aFGF),
Both are 16-kD sugar-free single-chain polypeptides having a molecular weight. The cell proliferation stimulating activity is said to be 30-100 times higher in basic fibroblast growth factor than in acidic fibroblast growth factor.
【０００６】本発明の発明者らは、ヒト正常メラノサイ
トを種々の細胞成長因子添加培地で培養し、無血清培地
の開発を行っていたところ、線維芽細胞成長因子がメラ
ノサイトのメラニン合成を強く抑制することを見い出し
た。メラニン合成を抑制するためには塩基性線維芽細胞
成長因子で５ng／ml以上、酸性線維芽細胞成長因子で５
０ng／ml以上の濃度が適当であり、この線維芽細胞成長
因子を用いることによりメラニン合成抑制が可能となっ
た。更には線維芽細胞成長因子がメラニン合成を抑制す
ることから、角化細胞などを刺激して線維芽細胞成長因
子を産生させる薬物等は、メラニン合成抑制剤となる可
能性がある。The inventors of the present invention cultivated human normal melanocytes in various cell growth factor-containing media and developed a serum-free medium, and fibroblast growth factor strongly suppressed melanin synthesis of melanocytes. I found out what to do. To suppress melanin synthesis, 5 ng / ml or more for basic fibroblast growth factor and 5 for acidic fibroblast growth factor
A concentration of 0 ng / ml or more is suitable, and the use of this fibroblast growth factor made it possible to suppress melanin synthesis. Furthermore, since fibroblast growth factor inhibits melanin synthesis, drugs that stimulate keratinocytes and the like to produce fibroblast growth factor may be melanin synthesis inhibitors.
【０００７】[0007]
【実施例】次に、本発明を実施例により説明するが、本
発明はこれら実施例に限定されるものではない。EXAMPLES The present invention will now be described with reference to examples, but the present invention is not limited to these examples.
【０００８】実施例１ 線維芽細胞成長因子のメラニン合成抑制活性 ヒト正常メラノサイトを１０ｃｍ２当り５ｘ１０４細胞
でまき込んだ。５ng／mlの濃度の塩基性線維芽細胞成長
因子（ｂＦＧＦ）または５０ng／mlの酸性線維芽細胞成
長因子（ａＦＧＦ）を含むＭＭ４培地で１２日間培養
し、細胞をトリプシン処理した後、１Ｎの水酸化ナトリ
ウムで可溶化し４７５nmでメラニン量を測定した。結果
を以下の表１に示す。Example 1 Inhibitory Activity of Fibroblast Growth Factor on Melanin Synthesis Human normal melanocytes were seeded at 5 × 10 4 cells per 10 cm 2 . After culturing in MM4 medium containing basic fibroblast growth factor (bFGF) at a concentration of 5 ng / ml or acidic fibroblast growth factor (aFGF) at 50 ng / ml for 12 days, the cells were trypsinized and then treated with 1N water. It was solubilized with sodium oxide and the amount of melanin was measured at 475 nm. The results are shown in Table 1 below.
【０００９】[0009]
【表１】 [Table 1]
【００１０】[0010]
【発明の効果】本発明によれば、肌に優しい生体由来物
質である塩基性線維芽細胞成長因子を用いることによ
り、メラニン合成を抑制し、色素沈着を優しく抑えるこ
とが可能となる。また、酸性線維芽細胞成長因子につい
ても高濃度でメラニン合成抑制剤として使用することが
可能である。更に、角化細胞などを刺激して線維芽細胞
成長因子を産生させる薬物等は、メラニン合成抑制剤と
なる可能性がある。According to the present invention, it is possible to suppress melanin synthesis and gently suppress pigmentation by using basic fibroblast growth factor, which is a biologically-friendly substance that is kind to the skin. Further, acidic fibroblast growth factor can also be used as a melanin synthesis inhibitor at a high concentration. Furthermore, a drug or the like that stimulates keratinocytes and the like to produce fibroblast growth factor may be a melanin synthesis inhibitor.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 7/48 38/00 // Ｃ０７Ｋ 14/50 8318−4Ｈ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display location A61K 7/48 38/00 // C07K 14/50 8318-4H
Claims (1)
ｆｉｂｒｏｂｌａｓｔ ｇｒｏｗｔｈ ｆａｃｔｏ
ｒ，ｂＦＧＦ）又は／及び酸性線維芽細胞成長因子（ａ
ｃｉｄｉｃ ｆｉｂｒｏｂｌａｓｔ ｇｒｏｗｔｈ ｆ
ａｃｔｏｒ，ａＦＧＦ）などの線維芽細胞成長因子を有
効成分とするメラニン合成抑制剤。1. Basic fibroblast growth factor (basic)
fibroblast grow facto
r, bFGF) or / and acidic fibroblast growth factor (a
cidic fibroblast grow f
A melanin synthesis inhibitor containing a fibroblast growth factor such as an actor, aFGF) as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11953494A JP3712074B2 (en) | 1994-05-09 | 1994-05-09 | Melanin synthesis inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11953494A JP3712074B2 (en) | 1994-05-09 | 1994-05-09 | Melanin synthesis inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07304686A true JPH07304686A (en) | 1995-11-21 |
| JP3712074B2 JP3712074B2 (en) | 2005-11-02 |
Family
ID=14763671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11953494A Expired - Fee Related JP3712074B2 (en) | 1994-05-09 | 1994-05-09 | Melanin synthesis inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3712074B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009119073A1 (en) * | 2008-03-28 | 2009-10-01 | 北海道公立大学法人札幌医科大学 | Agent for treating skin aging and scars |
-
1994
- 1994-05-09 JP JP11953494A patent/JP3712074B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009119073A1 (en) * | 2008-03-28 | 2009-10-01 | 北海道公立大学法人札幌医科大学 | Agent for treating skin aging and scars |
| EP2263683A1 (en) * | 2008-03-28 | 2010-12-22 | Labo Juversa Co., Ltd. | Agent for treating skin aging and scars |
| US8518878B2 (en) | 2008-03-28 | 2013-08-27 | Labo Juversa Co., Ltd. | Method for treating skin aging by administration of bFGF |
| EP2263683A4 (en) * | 2008-03-28 | 2013-11-13 | Labo Juversa Co Ltd | Agent for treating skin aging and scars |
| US9023792B2 (en) | 2008-03-28 | 2015-05-05 | Labo Juversa Co., Ltd. | Method for treating keloid and hypertrophic scars by administration of bFGF |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3712074B2 (en) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2063610C (en) | Method for the treatment of aging or photo-damaged skin | |
| US20080003311A1 (en) | Rosmarinus extracts for inhibiting/treating skin aging | |
| CN115634282A (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| AU2017276797A1 (en) | Peptides for hair growth | |
| AU2001275018B2 (en) | Composition and method for enhancing elasticity of tissue | |
| KR20050072799A (en) | Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil | |
| JP2002521457A (en) | Hair restoration and / or hair restoration compositions and methods | |
| US20230363999A1 (en) | Composition for treating hair loss or promoting hair growth comprising growth factor | |
| CA2598044C (en) | Cosmetic use of at least one natural ac-n-ser-asp-lys-pro-tetrapeptide or one of its analogues as agent for slowing down loss of hair and/or stimulating hair growth | |
| JPH07304686A (en) | Melanin synthesis-inhibiting agent | |
| DK0588477T3 (en) | Medical preparation comprising TCF-11 | |
| JP2009091325A (en) | Hair growth agent | |
| JPH03112912A (en) | Cosmetic composition | |
| JPH069349A (en) | Hair growing cosmetic | |
| WO2020111047A1 (en) | Composition for scalp and hair | |
| RU2321397C2 (en) | Composition for vitiligo treatment | |
| JPH0778026B2 (en) | Topical base for skin | |
| US6809075B1 (en) | Elastin peptide analogs and uses of same incombination with skin enhancing agents | |
| EP4292581A1 (en) | Hair repigmenting composition | |
| US11154482B2 (en) | Peptide, composition and method for anti-hair graying | |
| EP3831358A1 (en) | Peptides and compositions for use in cosmetics and medicine | |
| TWI664973B (en) | Application of lotus leaf extract for the treatment of pigmentation syndrome | |
| JP2004161639A (en) | Gray hair-preventing agent | |
| JPH06305941A (en) | Medicine and make-up goods to promote growth of hair | |
| JP2003267864A (en) | Hair-restoring and growing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050329 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050526 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050526 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050720 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050810 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080826 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090826 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090826 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100826 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110826 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120826 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130826 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |